References in periodicals archive ?
- Stockholm, Sweden-based pharmaceutical company Medivir AB (NASDAQ Stockholm: MVIR) has completed the pre-clinical safety studies for MIV-818, enabling the start of phase I clinical trials in 2018, the company said.
Medivir AB (STO: MVIR) announced on Sunday that Janssen Pharmaceuticals Inc (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen's assessment of market demand.
Medivir AB (STO: MVIR) on Tuesday reported profit after tax of SEK66.7m, or diluted EPS of SEK2.27, for the first quarter of 2015, from January 2015 to March 2015.
Medivir AB (OMX: MVIR) (STO: MVIRB), a research-based pharmaceutical company, announced on Wednesday a reorganisation of its management team in order to streamline and increase operational focus.
Medivir AB (OMX: MVIR), a research-based pharmaceutical company, announced today the availability of Olysio in all of the Nordic countries within the next few weeks for the treatment of adults with hepatitis C genotype 1 and 4 infection.
Research-based pharmaceutical company Medivir AB (OMX: MVIR) (STO: MVIRB.ST) announced today the division of its current R&D organisation into two parts, Discovery Research and Development.
Acronyms browser ?
Full browser ?
- MVK Datenmanagement GmbH